First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN) by unknown
RESEARCH Open Access
First results of the double-blind
randomized placebo-controlled multicenter
clinical trial of DIM-based therapy designed
as personalized approach to reverse
prostatic intraepithelial neoplasia (PIN)
Mikhail Paltsev1, Vsevolod Kiselev2, Vadim Drukh2, Ekaterina Muyzhnek3, Igor Kuznetsov4,
Evgeniya Andrianova4* and Pavel Baranovskiy1
Abstract
Background: Targeted pharmacological correction is used extensively in medical practice today. 3,3'-Diindolylmethane
(DIM) is known as a substance with various anticancer properties. An interim study of the efficacy of a new drug Infemin
on the basis of diindolylmethane (DIM) with improved bioavalability has been conducted.
Methods: The clinical trial had a multicenter, randomized, placebo-controlled, double-blind design and was carried out
in two parallel groups. The interim analysis of data included 21 patients diagnosed with a high-grade prostatic
intraepithelial neoplasia (PIN). Group 1 (11 patients) received Infemin in a dose of 900 mg of DIM a day, and group
2 (10 patients) received placebo. To assess the efficacy of therapy, the analysis of morphological index (MI) changes
based on the results of histological examinations of prostate biopsy specimens was performed, and a proportion of
patients with persistent PIN in 12 months after Infemin initiation was calculated. Researchers also evaluated prostate
size, urodynamic parameters (Qmax, Qave, Vres), IPSS, and QoL (quality of life) indices and International Index of Erectile
Function (IIEF) at 3, 6, 9, and 12 months after the Infemin administration start.
Results: After 12 months of treatment in the Infemin group, MI decreased from 0.50 to 0.08, while in the placebo
group, it increased from 0.27 to 0.58; the difference between the groups was statistically significant (p = 0.0003,
Mann-Whitney test). In 45.5 % of patients in the Infemin group, a complete regression of PIN was also observed,
while in the placebo group, PIN regression was not observed in any patients (p = 0.053, Yates’ corrected
chi-square). Study results in the Infemin group show improvement of maximal urinary flow rate Qmax (53.3 % increase
compared to the initial value); however, the statistical significance was not reached (p = 0.180, Mann-Whitney test) due
to the small sample size. Evaluation of other urodynamic parameters, prostate volume, quality of life, symptoms
reflecting urination disorder, and erectile dysfunction symptoms did not reveal significant differences between
the Infemin and placebo groups either which is probably due to the small sample size.
Conclusions: The intermediate results of the 21 patients in this multicenter, randomized, placebo-controlled,
double-blind study show that Infemin may be a promising drug candidate in patients with high-grade PIN.
Trial registration: www.chictr.org.cn ChiCTR-INR-15007496
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Background
Prostate cancer (PC) remains one of the most common
oncological problem in developed countries [1]. In 2012,
1.1 million new cases of PC and 307 thousand deaths from
this disease were recorded worldwide [2]. In Russia in
2013, about 31.5 thousand new cases of PC were diag-
nosed; at that, morbidity and mortality per 100 thousand
of male population were 47.51 and 16.72, respectively [3].
Prostatic intraepithelial neoplasia (PIN) is considered a
morphological equivalent of prostate precancer. It de-
velops as a result of proliferative changes of ductal epi-
thelium and acini of the prostate [4]. Many researchers
distinguish two forms of PIN: low-grade PIN (low-grade
prostatic intraepithelial neoplasia) and high-grade PIN
(high-grade prostatic intraepithelial neoplasia) depending
on pronouncement of cytological and structural changes of
the epithelium lining the prostate [4]. Nowadays, diagnosis
of PIN is usually made when changes specific to high-grade
PIN only are revealed since changes specific to low-grade
PIN are difficult to distinguish from the normal tissue and/
or atypical hyperplasia [5, 6]. Different researchers reveal
PIN as a disease predisposing PC in 38–100 % of patients
with a confirmed diagnosis of high-grade PIN [7].
It is generally recognized that the development of hyper-
plastic processes in the prostate is primarily associated
with hormonal imbalance [8]. With age in the prostate, in-
crease of enzyme 5-α-reductase production is observed;
this enzyme is responsible for synthesis of hormone 5α-
dihydrotestosterone (DHT), the active metabolite of male
sex hormone testosterone [9]. DHT with its increased an-
drogenic activity leads to the increased activity of genes
responsible for proliferation of prostate cells and, conse-
quently, to the development of hyperplasia.
Male sex hormones are known to manifest their bio-
logical activity via androgen receptors (ARs). Nevertheless,
blocking of hormonal stimuli (surgically or pharmacologic-
ally) does not always suppress the development of patho-
logical processes in the prostate. Many molecular cell
mechanisms have recently been revealed, stimulation of
which leads to the ARs biological function disturbance
and, consequently, to their abnormal activation by low
levels of androgens or other non-hormonal inducers and,
finally, to the development of androgen-refractory PC [10,
11]. Thus, it is becoming clearer that the adequate man-
agement of proliferative diseases of the prostate must
involve not only androgen-dependent but also other
androgen-independent elements of the pathogenesis.
Moreover, with age increase of the level of female
hormones, estrogens in men is observed. Estrogens stimu-
late stromal cells of the prostate via estrogen receptors as
well as influence ductal cells sensitive to estrogens which
results in abnormal cell proliferation and inflammation
[12], mechanisms playing an important part in the PC
pathogenesis [13].
Finally, malignant transformation of the prostatic cells
is accompanied by the epigenetic regulation disturbance,
particularly the increase of DNA methylation in pro-
moter regions and deacetylation of chromatin histones
resulting in epigenetic suppression of tumor suppressor
genes [14, 15].
For prevention of PC in patients at risk of this disease,
a search of pharmacological substances is being con-
ducted which would affect different elements of PIN
pathogenesis and allow suppression of transformation of
the prostatic cells into tumor cells.
An active substance indole-3-carbinol (I3C) and its
physiological metabolite 3,3′-diindolylmethane (DIM) are
compounds with confirmed multiple antitumor activity
[16]. I3C and DIM are reported to inhibit growth of
androgen-dependent and androgen-independent prostatic
cell cultures/tumors in vitro and in vivo [17, 18] due to
normalization of sex hormone level as well as balanced
regulation of androgen and estrogen receptor activity [19].
DIM is proved to be able to reactivate functioning of
tumor suppressor genes due to its DNA-demethylating
activity as well as its ability to inhibit activity of enzyme
histone deacetylases [20, 21]. Moreover, DIM promotes
interferon system activation, particularly IFN-γ [22], has a
strong anti-inflammatory activity [23], suppresses angio-
genesis factor VEGF activity, and markedly decreases
metastatic potential of cells acting via a wide range of
appropriate molecular targets [24, 25]. Finally, DIM mani-
fests selective activity towards a pool of so called cancer
stem cells which are currently considered the main source
of tumor recurrences and metastases [26].
In order to improve bioavailability of DIM, a new drug
Infemin was developed which constitutes a solution of
DIM and excipients into hard gelatin capsules [27].
We have conducted an interim analysis of the efficacy
data obtained from double-blind placebo-controlled clin-
ical study (phase IIa) of the efficacy of a new formulation
of DIM in patients with high-grade PIN. This article ad-
heres to CONSORT guidance for clinical trials reports.
Methods
Study design
The current clinical trial had a multicenter, randomized,
placebo-controlled, double-blind design and was carried
out in two equal parallel groups. The trial was conducted
in 18 study sites located in the Russian Federation. The
trial was approved by the Ministry of Health (resolution
number 779 dated 24.12.2013, http://grls.rosminzdrav.ru/
CIPermitionReg.aspx) and local Ethics Committees of the
study sites. The study included a total of 120 patients with
the following eligibility criteria.
The inclusion criteria were as follows: written informed
consent to participate in this study; diagnosis of prostatic
intraepithelial neoplasia (PIN), histologically verified in
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central reference laboratory; age of 18–80 years; ability to
carry out the procedures according to the trial protocol;
no official or other forms of relations to the persons
involved in the study interested in its outcomes; residual
urine volume ≤150 ml, PSA level ≤10 ng/ml.
The exclusion criteria were as follows: history of surgical
interventions on pelvic organs or their planning in the
nearest 12 months; maximal urinary flow rate <5 ml/s;
treatment of chronic prostatitis within 1 month before the
first study dose and treatment of prostatic hyperplasia or
PIN within 3 months before the first study dose; alcohol
or drug abuse; mental disorder and/or uncontrolled phys-
ical conditions; use of other investigational medicines
within 30 days before the first study dose; prostate cancer
and other malignant neoplasms; acute urine retention;
neurogenic dysfunctions and bladder ears; urethral stric-
ture; bladder neck sclerosis; urinary infections in a phase
of active inflammation; bladder calculi; diseases of cardio-
vascular and nervous system, concomitant renal or hep-
atic failure; positive hepatitis B or C, syphilis, or HIV tests.
Evaluation of the efficacy of therapy was performed
based on the changes of morphological index (MI) by
the moment of therapy completion (a statistically signifi-
cant decrease of MI compared to placebo). MI was de-
veloped by us in order to quantify neoplastic changes in
prostate and was calculated according to the formula:
MI ¼ f number of low‐grade PIN foci½  þ 2
 number of high‐grade PIN foci½  þ 3
 number of cancerous foci½ g
= number of biopsy fragments½ 
We developed this index as a measure of both severity
of neoplastic changes and their volume. The number of
biopsy fragments is used in MI formula in order to pre-
vent bias in cases when more or less than 12 biopsy
cores were taken.
The study’s hypothesis on the effectiveness of the drug
is that its use should lead to a difference in MI com-
pared to a placebo. Thus, if the MI by the end of the
study in the placebo group and in study group is equal
to h0 and h1, respectively, null and alternative hypoth-
eses can be formulated as follows:
H0: h0 = h1, there are no treatment-dependеnt differences
in the MI.
H1: h0 ≠ h1, there are treatment-dependеnt differences
in the MI.
The need to verify the hypothesis of the study (MI’s
difference between groups) was used as a basis in order
to perform calculations of the proper sample size. Study
statistical power was taken as 90 % (β = 0.1) and the
significance level (α) was taken as 0.05 (two-tailed). As it
was planned to perform two Holm-adjusted compari-
sons (interim and final), the sample size was calculated
according to the lowest α/2 level = 0.025. It was decided
that the hypothesized MI in study groups may reach 0.7
± 0.3; for the purposes of calculating the effectiveness in
the placebo group, this was taken as 0.9 ± 0.3 (on the
basis of expert opinions). For β = 0.10 and α = 0.025,
with the assumed difference between the MIs, we
needed 58 subjects with available data for analysis in the
each group. This value was increased to 60 assuming
3 % patient dropout rate.
Calculation of the sample size was performed as
follows:
n ¼ Zα þ Zβ
 2  Sxe2 þ Sxc2
 
=δ2 ;
where n is the sample size for each group, Sxe is the
standard deviation in the first group, Sxc is the standard
deviation in the second group, δ is the difference
between groups’ MIs, and Zα and Zβ are the critical
values of normal distribution corresponding to a given
level of errors type 1 and 2.
A randomization list was provided by the sponsor
before the beginning of the study using SPSS Statistics
version 20.0.0 computer software. Block randomization
was used with a block size equal to 2, each block con-
taining one patient who was assigned an active drug and
one patient who was assigned a placebo. The blinded
treatment assignment procedure was carried out by
sending a fax to the sponsor from the study site. The fax
contained a randomization request form with informa-
tion on the patient’s conformity with the inclusion/
exclusion criteria. The sponsor’s response, sent by the
fax to the study site, consisted of a patient report form
with a unique identification number and drug identifica-
tion code on the packaging (in accordance with the
randomization sheet, packages of the preparation con-
tained an appropriate daily dose of the active drug or a
placebo). The randomization sheet was kept solely by
the sponsor. Patient flow diagram is shown in Fig. 1.
Patients and treatment
Twenty-one patients, age 52–78 years old, with histo-
logically verified diagnosis of high-grade prostatic
intraepithelial neoplasia (PIN) were included in current
interim analysis as they have completed the trial. Initially,
all the patients had a residual urine volume ≤150 ml, PSA
level ≤10 ng/ml, and maximal urinary flow rate ≥5 ml/s.
Twenty-eight days before the active therapy, patients
underwent screening during which their medical history
was taken; physical examination and laboratory test were
performed. Laboratory tests included complete blood
count, clinical urine test, blood chemistry (general protein,
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glucose, creatinine, general bilirubin, aspartate aminotrans-
ferase (AST) and alanine transaminase (ALT) activity), and
serum PSA level. Also, hepatitis B and C and HIV and RW
blood diagnostics were performed.
In the course of initial screening, ECG data (PQ, QRS,
QT) of patients were obtained, and urological checkup
with digital rectal examination, prostate biopsy, uroflow-
metry, transrectal ultrasonography (TRUS) with retained
urine determining, and completion of questionnaires
(IPSS + QoL, IIEF) were performed.
After signing the informed consent and checking of
eligibility criteria, the participants were divided into
two groups. Recruitment began on 30 January 2014 and
has been finished on 28 July 2015, the day when the
120th patient was randomized. Of the total of 120
patients, three patients (one in active drug group and
two in placebo group) were lost to follow-up because
they decided to stop participating in the trial (to the
moment of interim analysis). Twenty-one patients who
completed the study to the moment were included in
the current interim analysis. Patients of group 1 (11 pa-
tients) were prescribed with Infemin in the initial dose
of 900 mg of DIM a day (three capsules two times a
day); group 2 (10 patients) received placebo (three cap-
sules two times a day). Active therapy was performed
for 12 months with control visits at the beginning of
study, in 3, 6, and 9 months after the treatment start.
Ultrasonography-guided 12-core prostate biopsy was
performed for every patient during the screening and at
the end of study (after 12 months of treatment). In cases
of significant PSA increase and clinical symptoms, pro-
gression biopsy might be performed at 3, 6, or 9 months
after the trial start too. Tissue fragments were taken
from both prostate lobes (six from the left and right).
Specimens were fixed in 10 % buffered formalin solution
and then embedded in paraffin. Sections were stained
with hematoxylin and eosin for routine histological
examination, as well as for immunohistochemical studies
(when needed) in a central reference laboratory.
A proportion of the patients with persistent PIN/BPH in
12 months after the Infemin therapy start and a proportion
of patients with PC in 12 months after the Infemin therapy
start were used as additional efficacy criteria. Researchers
also determined (1) prostate size (mL) in 3, 6, 9, and
12 months after the Infemin administration start (using the
formula [width × height × length] × 0.70); (2) urodynamic
parameters: maximal urinary flow rate (Qmax), average
urinary flow rate (Qave), residual urine volume (Vres) in 3,
6, 9, and 12 months after the Infemin administration start;
and (3) general IPSS indixes (symptom intensity), QoL
Fig. 1 Patient flowchart to the moment of current interim analysis
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(quality of life), International Index of Erectile Function
(IIEF), and IEEF subindices (A, B, C, D, E) in 3, 6, 9, and
12 months after the Infemin administration start. Analysis
of the efficacy parameters was performed based on the
results of histological examinations of prostate biopsy spec-
imens and TRUS, urodynamic parameters and data of
IPSS, and QoL and IIEF questionnaires.
Test compositions
Infemin capsules (“IlmixGroup,” Closed Joint Stock
Company, Russia) contain DIM (150 mg), cod liver oil
(20 mg), α-tocopherol acetate (5 mg), and polysorbate
80 as an excipient (575 mg). Comparator drug—placebo,
contains polysorbate 80 (750 mg). Active drug and pla-
cebo had the same organoleptic characteristics.
Statistical analysis
All calculated parameters are expressed as Me (Q1; Q3),
where Me is median and (Q1; Q3) is interquartile range:
upper limit of lower quartile (Q1) and lower limit of
upper quartile (Q3). As the number of patients was too
low to use parametric methods, to determine statistical sig-
nificance of differences between groups, Mann-Whitney U
test and Yates’ corrected chi-square (for binary variables)
were used. Differences in current interim analysis were
considered statistically significant when р < 0.025 according
to Holm adjustment for multiple comparisons. Statistical
analysis of study results was performed using SPSS Statis-
tics 19.0 and Microsoft Excel 2007 software packages.
Results
The interim analysis included male patients, age 52–
78 years old, with verified diagnosis of high-grade PIN.
The two study groups (active therapy and control) did not
differ from each other in main demographic parameters
(race, age, smoking status) and in the initial condition
(history of diseases and concomitant diseases) before the
inclusion into the study. In study groups, no significant
differences in main physical parameters, laboratory pa-
rameters of blood and urine, ECG, urodynamic parame-
ters, and PSA level were determined. The groups did not
differ in IPSS, QoL, and IIEF indices (general and five sub-
indices A, B, С, D, E). The data obtained suggested the
possibility of assembling the patient into a group for ana-
lysis considering the study sample to be homogeneous.
Patients in group 1 (11 patients) were prescribed with
Infemin orally in the initial dose of 900 mg of DIM a
day (three capsules two times a day); patients of group 2
(10 patients) received three capsules of placebo two
times a day. The therapy was conducted for 12 months.
Based on the results of the interim data analysis
obtained during this randomized double-blind placebo-
controlled study of the efficacy of Infemin in treatment
of PIN, changes of the main efficacy criterion, morpho-
logical index, were assessed (Fig. 2).
It was determined that while before the treatment in
the Infemin group MI was 0.50 (Q1 0.20; Q3 0.93),
after 12 months of the therapy, MI decreased to 0.08
(Q1 0.00; Q3 0.20). At the same time in the placebo
group, an increase of MI from 0.27 (Q1 0.17; Q3 0.44)
to 0.58 (Q1 0.42; Q3 0.73) was observed. Statistical ana-
lysis in study groups in 12 months showed that in the
Infemin group MI was significantly lower (p = 0.0003,
Mann-Whitney test) compared to the placebo group,
0.08 versus 0.58, respectively.
The most important additional efficacy criterion for
the treatment of PIN is a complete response rate. In this
study, a proportion of patients with persistent high-
grade PIN was assessed based on the results of the treat-
ment with Infemin. It was determined that the therapy
Fig. 2 Morphological index value in patients diagnosed with high-grade PIN before and after 12 months of treatment in the Infemin and placebo
groups. Data are expressed as Me (Q1; Q3)
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with Infemin conducted for 12 months resulted in the
complete regression of PIN in 45.5 % of patients (five of
11 patients). At the same time, the regression of PIN
was not observed in either of patients in the placebo
group (Fig. 3). However, with such a sample size, statis-
tical significance of the differences between the Infemin
and placebo groups in this parameter was not reached
(p = 0.053, Yates’ corrected chi-square).
After 12 months of the follow-up, PC was determined
in three patients (only in the placebo group −30.0 %). To
this moment, the difference in PIN progression to PC
rate between groups has not reached statistical signifi-
cance (p = 0.181, Yates’ corrected chi-square).
In the analysis of the additional criteria of the effi-
cacy of therapy, no significant changes (Mann-Whitney
test) were observed to the end of follow-up period
(Table 1).
Based on the comparison results for the treatment
efficacy in the study groups in quality of life (QoL),
symptoms reflecting urination disorder (IPSS index),
and various aspects of patients’ sexual function (IIEF
index and A, B, C, D, E subindices), no significant
differences were determined after 12 months of the
therapy (Mann-Whitney test). Quantitative values of
the investigated parameters are showed in Tables 1
and 2.
Discussion
This study represents interim analysis of data obtained in
phase IIa clinical trial; the main aim of this trial is a proof
of concept. We performed an interim study in order to
show whether the investigative drug has a treating poten-
tial against PIN. Results of this interim double-blind
placebo-controlled study confirm that the administration
Fig. 3 Proportion of patients with persistent high-grade PIN in the Infemin and placebo groups in 12 months after the treatment start
Table 1 Changes of the treatment efficacy parameters in the Infemin and placebo groups
Parameter Infemin Me (Q1;Q3) Placebo Me (Q1;Q3)
Screening 12 months Screening 12 months
Prostate size, mL 52 (37;71) 65 (54;67) 59 (48;75) 42 (20;109)
Maximal urinary flow rate (Qmax), mL/s 10 (7;14) 17 (14;17) 17 (12;19) 15 (15;16)
Average urinary flow rate (Qave), mL/s 6 (3;7) 9 (7;10) 9 (7;11) 10 (8;12)
Residual urine volume (Vres), mL 30 (14;60) 42 (15;65) 23 (18;40) 25 (0;35)
Symptom intensity (IPSS index) 14 (11;20) 4 (2;6) 14 (6;19) 7 (6;9)
Quality of life (QoL index) 3 (3;3) 1 (1;1) 2 (2;5) 2 (2;6)
Erectile dysfunction (IIEF index) 26 (6;43) 51 (46;55) 28 (8;51) 63 (35;65)
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of Infemin for 12 months in patients diagnosed with high-
grade PIN results in marked improvement of the morpho-
logical structure of prostate (MI decrease from 0.50 to
0.08) which is indicative of the complete suppression of
the proliferative activity of prostatic epithelium induced
by this drug. In 45.5 % of patients in the Infemin group, a
complete regression of PIN was also observed which is an
important additional criterion of the treatment efficacy;
however, the significance of the differences was not
reached with such a small number of patients. The assess-
ment of urodynamic parameters, prostate volume, quality
of life, symptoms reflecting urination disorder, and symp-
toms of erectile dysfunction did not revealed statistically
significant differences compared to the placebo group
which is probably due to the insufficient sample size. Im-
provement of the condition for these parameters will be
analyzed for a larger number of patients.
The first data about DIM efficacy in PIN patients are of
special interest because there is no cure for this condition
at the moment. Very few publications were focused on
this problem. The only promising agent known to this
time is green tea extract (catechins). It was reported that
green tea catechins were effective in high-grade PIN pa-
tients [28]. High-grade PIN often leads to prostate cancer,
and this group of patients needs effective treatment as a
personalized approach for PC risk reduction. Our concept
is that PC chemoprevention should be focused at high-
grade PIN patients. We are going to present the complete
results of this phase IIa trial later, and during the IIb
phase, clinical trial dose ranging and pharmacodynamic
studies will be performed. Future pharmacoepidemiology
studies are needed also to obtain the final proof of this
concept.
Novel DIM-based formulation Infemin with high bio-
availability may represent effective targeted treatment for
patients with high-grade PIN. Many practical applications
of DIM are based on its ability to target multiple molecu-
lar and biochemical signaling pathways. Therapy with
Infemin may become a preventive measure that contrib-
utes to the suppression of the pathological processes in
prostate at the early stage. The results from the current
trial provide preliminary evidence that DIM-based formu-
lation may be a promising medication for individuals at
high risk of PC. Previously, we obtained preliminary data
indicating a good tolerability profile of Infemin in patients
with PIN [29]. We believe that prostate cancer risk might
be diminished thanks to a unique therapeutic potential of
this active substance.
Conclusions
The presented results of the efficacy study of the Infemin
are intermediate (the study is scheduled to be completed
in 2016). The main limitation of this trial is a small num-
ber of patients in the interim analysis. However, based on
these intermediate results, already obtained for the 21 pa-
tients with high-grade prostatic intraepithelial neoplasia, a
potentially favorable efficacy profile of the Infemin has
been demonstrated. Therefore, it is concluded that Infe-
min may be a promising drug candidate for the treatment
of high-grade PIN and, thus, for the prevention of prostate
cancer in these patients. Further clinical studies are
needed to detect the efficacy and safety of the drug.
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Table 2 Changes of various aspects of patients’ sexual function (IIEF index and A, B, C, D, E subindices) in the Infemin and placebo
groups
Parameter Infemin Me (Q1;Q3) Placebo Me (Q1;Q3)
Screening 12 months Screening 12 months
Erectile function itself subindex (A) 12 (4;21) 22 (18;25) 28 (15;29) 6 (1;26)
Orgasmic function subindex (B) 4 (0;10) 7 (6;7) 4 (0;10) 10 (5;10)
Libido intensity subindex (C) 4 (3;6) 7 (6;7) 5 (2;6) 7 (5;8)
Satisfaction with sexual intercourse subindex (D) 6 (0;8) 10 (10;10) 6 (0;9) 11 (5;11)
General satisfaction with sexual function subindex (E) 4 (3;6) 6 (6;6) 5 (2;6) 8 (5;8)
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